These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15295043)

  • 1. Treatment of heart failure with spironolactone--trial and tribulations.
    McMurray JJ; O'Meara E
    N Engl J Med; 2004 Aug; 351(6):526-8. PubMed ID: 15295043
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperkalemia after the publication of RALES.
    Witham MD; Gillespie ND; Struthers AD
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580679
    [No Abstract]   [Full Text] [Related]  

  • 3. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hyperkalemia, heart failure and reduced renal function].
    Bugge JF
    Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1354-5. PubMed ID: 20596118
    [No Abstract]   [Full Text] [Related]  

  • 7. Hyperkalemia after the publication of RALES.
    Newsome BB; Warnock DG
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580678
    [No Abstract]   [Full Text] [Related]  

  • 8. [An elderly man with known heart failure admitted with cardiogenic shock].
    Hovland A; Fagerheim AK; Hardersen R; Nielsen EW
    Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1352-4. PubMed ID: 20596117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperkalemia after the publication of RALES.
    Goldfarb DS
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15575065
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperkalemia after the publication of RALES.
    Cavallari L; Vaitkus P; Groo V
    N Engl J Med; 2004 Dec; 351(23):2448-50; author reply 2448-50. PubMed ID: 15580677
    [No Abstract]   [Full Text] [Related]  

  • 11. Study warns of danger of combining spironolactone and ACE inhibitors in heart patients.
    Gottlieb S
    BMJ; 2004 Aug; 329(7463):420. PubMed ID: 15321896
    [No Abstract]   [Full Text] [Related]  

  • 12. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 13. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
    Erden I; Yalcin S; Ozhan H
    Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.
    Witham MD; Gillespie ND; Struthers AD
    Br J Clin Pharmacol; 2004 Nov; 58(5):554-7. PubMed ID: 15521905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.
    Matsumoto Y; Kageyama S; Yakushigawa T; Arihara K; Sugiyama T; Mori Y; Sugiyama H; Ohmura H; Shio N
    Cardiology; 2009; 114(1):32-8. PubMed ID: 19342857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.